Boehringer Ingelheim Sees Lung Function Improvement In Tiotropium Phase III Trials
This article was originally published in PharmAsia News
German company Boehringer Ingelheim announced positive results of its Phase III trials with bronchodilator Tiotropium for patients suffering from severe asthma.
You may also be interested in...
Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.
US pharmacy group says that 10 to 12 states have indicated through an informal survey that they do not have the manpower or funding to implement the US FDA’s final MOU on inordinate compounding. They say what is at stake in these states is patient access to compounded medicines.
Mayo Clinic announces AI-based partnerships with Google and voice-analysis company Vocalis Health this week.